The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2021 | Key trials in CTCL
Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, talks on a response criterion for clinical trials assessing treatments for cutaneous T-cell lymphoma (CTCL) which 3 contemporary trials have utilized and outlines these trials. Dr Pinter-Brown talks on the Phase III ALCANZA study (NCT01578499) of brentuximab vedotin versus methotrexate or bexarotene and the Phase III MAVORIC study (NCT01728805) on mogamulizumab versus vorinostat for relapsed/refractory CTCL. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
